Faron, etusivu

Faron Pharmaceuticals Ltd: Notice of Half-Year Financial Results

Faron Pharmaceuticals Ltd | Company announcement | August 19, 2026 at 09:00:00 EEST

Faron Pharmaceuticals will publish its half-year financial results for January-June 2026 on Wednesday 26 August 2026

TURKU, Finland – Faron Pharmaceuticals Ltd. (AIM: FARN, First North: FARON), a clinical-stage biopharmaceutical company focused on tackling cancers through novel immunological pathways, will report its unaudited half-year financial results for the six months ended 30 June 2026, on Wednesday, 26 August 2026.

A virtual briefing and Q&A session for investors, analysts and media will be hosted by Dr. Juho Jalkanen, Chief Executive Officer and Jurriaan Dekkers, Chief Financial Officer at 08:00 am (EDT) / 1:00 pm (BST) / 3:00 pm (EEST) on Wednesday, 26 August 2026. Webcast registration link: Faron 2026 Half-Year Financial Results

The half-year report, presentation, and a replay of the webcast will be published afterward on the Company’s website at: Reports and presentations – Faron

For more information, please contact:

IR Partners, Finland
(Media)

Kare Laukkanen
+358 50 553 9535 / +44 7 469 766 223
kare.laukkanen@irpartners.fi
FINN Partners, US
(Media) 
Alyssa Paldo 		 +1 847 791-8085 
alyssa.paldo@finnpartners.com
Cairn Financial Advisers LLP
(Nominated Adviser and Broker)
Sandy Jamieson, Jo Turner		 +44 (0) 207 213 0880
Sisu Partners Oy
(Certified Adviser on Nasdaq First North)
Juha Karttunen
Jukka Järvelä		 +358 (0)40 555 4727
+358 (0)50 553 8990

About bexmarilimab

Bexmarilimab is Faron’s wholly owned, investigational immunotherapy designed to overcome resistance to existing treatments and optimize clinical outcomes, by targeting myeloid cell function and igniting the immune system. Bexmarilimab binds to Clever-1, an immunosuppressive receptor found on macrophages leading to tumor growth and metastases (i.e. helps cancer evade the immune system). By targeting the Clever-1 receptor on macrophages, bexmarilimab alters the tumor microenvironment, reprogramming macrophages from an immunosuppressive (M2) state to an immunostimulatory (M1) one, upregulating interferon production and priming the immune system to attack tumors and sensitizing cancer cells to standard of care.

About Faron Pharmaceuticals Ltd.

Faron (AIM: FARN, First North: FARON) is a global, clinical-stage biopharmaceutical company, focused on tackling cancers via novel immunotherapies. Its mission is to bring the promise of immunotherapy to a broader population by uncovering novel ways to control and harness the power of the immune system. The Company’s lead asset is bexmarilimab, a novel anti-Clever-1 humanized antibody, with the potential to remove immunosuppression of cancers through reprogramming myeloid cell function. Bexmarilimab is being investigated in Phase 1/2 clinical trials as a potential therapy for patients with hematological cancers in combination with other standard treatments. Further information is available at www.faron.com.

FARON PHARMACEUTICALS LTD: HOLDING(S) IN COMPANY

Faron Pharmaceuticals Ltd | Company announcement | August 05, 2026 at 14:00:00 EEST

TR-1: Standard form for notification of major holdings

NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer in Microsoft Word format if possible) i
1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached ii: Faron Pharmaceuticals OY
1b. Please indicate if the issuer is a non-UK issuer (please mark with an “X” if appropriate)
Non-UK issuer X
2. Reason for the notification (please mark the appropriate box or boxes with an “X”)
An acquisition or disposal of voting rights X
An acquisition or disposal of financial instruments
An event changing the breakdown of voting rights
Other (please specify) iii:
3. Details of person subject to the notification obligation iv
Name Heights Capital Management, Inc.
City and country of registered office (if applicable) San Francisco, California
4. Full name of shareholder(s) (if different from 3.) v
Name CVI Investments, Inc.
City and country of registered office (if applicable) Cayman Islands
5. Date on which the threshold was crossed or reached vi: 04/08/2026
6. Date on which issuer notified (DD/MM/YYYY): 04/08/2026
7. Total positions of person(s) subject to the notification obligation
% of voting rights attached to shares (total of 8. A) % of voting rights through financial instruments
(total of 8.B 1 + 8.B 2)		 Total of both in % (8.A + 8.B) Total number of voting rights held in issuer (8.A + 8.B) vii
Resulting situation on the date on which threshold was crossed or reached 9.41% 11.30% 20.72% 47,211,351
Position of previous notification (if
applicable)		 7.99% 12.53% 20.52%
8. Notified details of the resulting situation on the date on which the threshold was crossed or reached viii
A: Voting rights attached to shares
Class/type of
shares
ISIN code (if possible)		 Number of voting rights ix % of voting rights
Direct
(DTR5.1)		 Indirect
(DTR5.2.1)		 Direct
(DTR5.1)		 Indirect
(DTR5.2.1)
21,451,351 25,760,000 9.41% 11.30%
SUBTOTAL 8. A 47,211,351 20.72%
B 1: Financial Instruments according to DTR5.3.1R (1) (a)
Type of financial instrument Expiration
date x		 Exercise/
Conversion Period xi		 Number of voting rights that may be acquired if the instrument is
exercised/converted.		 % of voting rights
Convertible Bond 08/02/2027 Anytime until maturity 10,080,000 4.42%
Convertible Bond 12/02/2028 Anytime until maturity 15,680,000 6.88%
SUBTOTAL 8. B 1 25,760,000 11.30%
B 2: Financial Instruments with similar economic effect according to DTR5.3.1R (1) (b)
Type of financial instrument Expiration
date x		 Exercise/
Conversion Period xi		 Physical or cash
Settlement xii		 Number of voting rights % of voting rights
SUBTOTAL 8.B.2
9. Information in relation to the person subject to the notification obligation (please mark the
applicable box with an “X”)
Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer xiii
Full chain of controlled undertakings through which the voting rights and/or the
financial instruments are effectively held starting with the ultimate controlling natural person or legal entity (please add additional rows as necessary) xiv
Name xv % of voting rights if it equals or is higher than the notifiable threshold % of voting rights through financial instruments if it equals or is higher than the notifiable threshold Total of both if it equals or is higher than the notifiable threshold
Heights Capital Management, Inc. 9.41% 11.30% 20.72%
CVI Investments, Inc. 9.41% 11.30% 20.72%
10. In case of proxy voting, please identify:
Name of the proxy holder
The number and % of voting rights held
The date until which the voting rights will be held
11. Additional information xvi
None
Place of completion London, United Kingdom
Date of completion 04.08.2026

FARON PHARMACEUTICALS LTD: HOLDING(S) IN COMPANY

Faron Pharmaceuticals Ltd | Company announcement | August 04, 2026 at 16:00:00 EEST

TR-1: Standard form for notification of major holdings

NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) i
1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached ii: Faron Pharmaceuticals Ltd
1b. Please indicate if the issuer is a non-UK issuer (please mark with an “X” if appropriate)
Non-UK issuer X
2. Reason for the notification (please mark the appropriate box or boxes with an “X”)
An acquisition or disposal of voting rights
An acquisition or disposal of financial instruments
An event changing the breakdown of voting rights X
Other (please specify) iii: Amortisation of the First and Second Tranche Bonds with treasury shares X
3. Details of person subject to the notification obligation iv
Name Faron Pharmaceuticals Ltd
City and country of registered office (if applicable) Turku, Finland
4. Full name of shareholder(s) (if different from 3.) v
Name
City and country of registered office (if applicable)
5. Date on which the threshold was crossed or reached vi: 3.8.2026
6. Date on which issuer notified (DD/MM/YYYY): 3.8.2026
7. Total positions of person(s) subject to the notification obligation
% of voting rights attached to shares (total of 8. A) % of voting rights through financial instruments
(total of 8.B 1 + 8.B 2)		 Total of both in % (8.A + 8.B) Total number of voting rights held in issuer (8.A + 8.B) vii
Resulting situation on the date on which threshold was crossed or reached 9.37% 9.37% 21,342,679
Position of previous notification (if
applicable)		 10.97% 10.97%
8. Notified details of the resulting situation on the date on which the threshold was crossed or reached viii
A: Voting rights attached to shares
Class/type of
shares
ISIN code (if possible)		 Number of voting rights ix % of voting rights
Direct
(DTR5.1)		 Indirect
(DTR5.2.1)		 Direct
(DTR5.1)		 Indirect
(DTR5.2.1)
FI4000153309 21,342,679 9.37%
SUBTOTAL 8. A 21,342,679 9.37%
B 1: Financial Instruments according to DTR5.3.1R (1) (a)
Type of financial instrument Expiration
date x		 Exercise/
Conversion Period xi		 Number of voting rights that may be acquired if the instrument is
exercised/converted.		 % of voting rights
SUBTOTAL 8. B 1
B 2: Financial Instruments with similar economic effect according to DTR5.3.1R (1) (b)
Type of financial instrument Expiration
date x		 Exercise/
Conversion Period xi		 Physical or cash
Settlement xii		 Number of voting rights % of voting rights
SUBTOTAL 8.B.2
9. Information in relation to the person subject to the notification obligation (please mark the
applicable box with an “X”)
Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer xiii x
Full chain of controlled undertakings through which the voting rights and/or the
financial instruments are effectively held starting with the ultimate controlling natural person or legal entity (please add additional rows as necessary) xiv
Name xv % of voting rights if it equals or is higher than the notifiable threshold % of voting rights through financial instruments if it equals or is higher than the notifiable threshold Total of both if it equals or is higher than the notifiable threshold
Faron Pharmaceuticals Ltd 9.37% 9.37%
10. In case of proxy voting, please identify:
Name of the proxy holder
The number and % of voting rights held
The date until which the voting rights will be held
11. Additional information xvi
3.8.2026 Company announcement: Faron Pharmaceuticals Ltd: Approval of Share Subscriptions Based on Special Rights in connection with Amortisation of the First and Second Tranche Bonds 
Place of completion Turku, Finland
Date of completion 3.8.2026

Faron Pharmaceuticals Ltd: Approval of Share Subscriptions Based on Special Rights in connection with Amortisation of the First and Second Tranche Bonds

Faron Pharmaceuticals Ltd | Company announcement | August 03, 2026 at 15:00:00 EEST

Turku, Finland – Faron Pharmaceuticals Ltd. (AIM: FARN, First North: FARON), a clinical-stage biopharmaceutical company developing novel immunotherapies, announces that the Company has approved the exercise of 3,657,321 special rights entitling to 3,657,321 shares in the Company, for an aggregate subscription price of EUR 1,578,499.74 in connection with the scheduled amortisation payment of the First and Second Tranche Bonds (as defined below), occurred on 3 August 2026.

The Company announced on 3 April 2025 that it had entered into a convertible bond arrangement for up to EUR 35 million with an entity managed by Heights Capital Management, Inc. (“HCM”) and resolved upon the issuance of amortising senior unsecured convertible bonds with an aggregated principal amount of EUR 15 million (the “First Tranche Bonds”) due 2 April 2028 to HCM, convertible into new and/or existing shares in the Company (the “Shares”). On 11 December 2025 the Company announced that it had resolved upon the issuance of a second tranche of convertible bonds amounting to EUR 10 million (the “Second Tranche Bonds”) due 2 December 2028, to HCM, convertible into new and/or existing Shares in the Company. As previously announced, the Board of Directors of Faron has resolved to make amortisations and interest payments by converting the relevant amounts due into Shares (“Share Settlement Option”), unless it separately decides to make payments in cash. The exercise of the Company’s Share Settlement Option is effected by the bondholders exercising special rights entitling into Shares, as referred to in Chapter 10 of the Finnish Companies Act (“Special Rights”), issued in connection with the issuance of the First Tranche Bonds and the Second Tranche Bonds.

The Company has received a scheduled amortised payment notice from the bondholder for an aggregate amortised payment amount (including accrued interest) of EUR 913,500 for First Tranche bonds and EUR 665,000 for Second Tranche Bonds. Therefore, total aggregate amortised payment amount (including accrued interest) is EUR 1,578,500. As the Company has exercised its Share Settlement Option, the subscription price for the Shares subscribed for by the bondholder is EUR 0.4316 per Share being the lower of i) conversion price on the amortization date (EUR 0.50) or ii) 90 per cent of the lowest of (i) the volume weighted average price (“VWAP”) of a Share on the relevant payment date (3 August 2026), and (ii) the lowest of the VWAPs of a Share on each of the five consecutive dealing days ending on (and including) the dealing day immediately preceding the relevant payment date. Therefore, the Company has approved the exercise of 3,657,321 Special Rights entitling to 3,657,321 new Shares in total, for an aggregate subscription price of EUR 1,578,500. Of those Shares 2,116,543 are used to amortize the First Tranche Bonds (including accrued interest) and 1,540,778 to amortize the Second Tranche Bonds (including accrued interest). The subscription price for the Shares subscribed for pursuant to the Special Rights is paid by setting off the Company’s debt to pay relevant amounts due under the First Tranche Bonds and the Second Tranche Bonds and recorded into the reserve for invested unrestricted equity.

The 3,657,321 shares subscribed for are shares already held by the Company in treasury. The Shares rank pari passu in all respects with the existing shares of the Company.

Following the amortisation, the aggregate number of shares in the Company is 227,881,315 and of these shares, the Company holds 21,342,679 in treasury. The shares held in treasury by the Company do not confer a right to dividends or other shareholder rights.

For more information, please contact:

IR Partners, Finland
(Media)
Kare Laukkanen		 +358 50 553 9535 / +44 7 469 766 223
kare.laukkanen@irpartners.fi
FINN Partners, US
(Media) 
Alyssa Paldo 		 +1 847 791-8085 
alyssa.paldo@finnpartners.com
Cairn Financial Advisers LLP
(Nominated Adviser and Broker)
Sandy Jamieson, Jo Turner		 +44 (0) 207 213 0880
Sisu Partners Oy
(Certified Adviser on Nasdaq First North)
Juha Karttunen
Jukka Järvelä		 +358 (0)40 555 4727
+358 (0)50 553 8990

About Faron Pharmaceuticals Ltd

Faron (AIM: FARN, First North: FARON) is a global, clinical-stage biopharmaceutical company, focused on tackling cancers via novel immunotherapies. Its mission is to bring the promise of immunotherapy to a broader population by uncovering novel ways to control and harness the power of the immune system. The Company’s lead asset is bexmarilimab, a novel anti-Clever-1 humanized antibody, with the potential to remove immunosuppression of cancers through reprogramming myeloid cell function. Bexmarilimab is being investigated in Phase I/II clinical trials as a potential therapy for patients with hematological cancers in combination with other standard treatments. Further information is available at www.faron.com.

Forward-Looking Statements

Certain statements in this announcement are, or may be deemed to be, forward-looking statements. Forward looking statements are identified by their use of terms and phrases such as ”believe”, ”could”, “should”, “expect”, “hope”, “seek”, ”envisage”, ”estimate”, ”intend”, ”may”, ”plan”, ”potentially”, ”will” or the negative of those, variations or comparable expressions, including references to assumptions. These forward-looking statements are not based on historical facts but rather on the Directors’ current expectations and assumptions regarding the Company’s future growth, results of operations, performance, future capital and other expenditures (including the amount, nature and sources of funding thereof), competitive advantages, business prospects and opportunities. Such forward-looking statements reflect the Directors’ current beliefs and assumptions and are based on information currently available to the Directors.

A number of factors could cause actual results to differ materially from the results and expectations discussed in the forward-looking statements, many of which are beyond the control of the Company. In addition, other factors which could cause actual results to differ materially include the ability of the Company to successfully license its programs within the anticipated timeframe or at all, risks associated with vulnerability to general economic and business conditions, competition, environmental and other regulatory changes, actions by governmental authorities, the availability of capital markets or other sources of funding, reliance on key personnel, uninsured and underinsured losses and other factors. Although any forward-looking statements contained in this announcement are based upon what the Directors believe to be reasonable assumptions, the Company cannot assure investors that actual results will be consistent with such forward-looking statements. Accordingly, readers are cautioned not to place undue reliance on forward-looking statements. Subject to any continuing obligations under applicable law or any relevant AIM Rule requirements, in providing this information the Company does not undertake any obligation to publicly update or revise any of the forward-looking statements or to advise of any change in events, conditions or circumstances on which any such statement is based.

Inside Information: Faron announces encouraging first overall survival data from frontline higher-risk (HR) MDS patients in the BEXMAB phase 1/2 trial

Faron Pharmaceuticals Ltd | Company announcement | July 27, 2026 at 09:00:00 EEST

Inside Information: After a median follow-up of 14.9 months, median overall survival has not yet been reached in frontline HR MDS without TP53 mutations, nor has it yet been reached for monoallelic TP53 mutated patients. For patients with biallelic TP53 mutations the median OS is 8.8 months in line with historical results in this highly aggressive population.

TURKU, FINLAND – Faron Pharmaceuticals Ltd. (AIM: FARN, First North: FARON), a global, clinical-stage biopharmaceutical company focused on creating innovative cancer treatments that leverage the patient’s own immune system, today announced that it has conducted its first overall survival (OS) data cut from treatment-naïve higher-risk myelodysplastic syndrome (HR-MDS) patients enrolled in the BEXMAB trial. At this time, after a median follow-up of 14.9 months, the only subgroup to have hit the median is the biallelic TP53 mutated population. This subgroup, historically associated with very poor outcomes, achieved a median OS of 8.8 months, which is in line with historical data and reassuring given the complex cytogenetics within the BEXMAB biallelic patient population. Other subgroups: monoallelic TP53 mutated and wildtype patients have still not reached their median OS.

The BEXMAB trial is an open-label Phase 1/2 study investigating bexmarilimab, Faron’s novel anti-Clever-1 immunotherapy, in combination with standard-of-care azacitidine in patients with higher-risk myelodysplastic syndromes. Of the 21 treatment-naïve HR-MDS patients, 48% harboured TP53 mutations, a well-established adverse prognostic factor associated with inferior survival outcomes. Of the TP53 mutated patients (with known allele frequency data), 33% had monoallelic TP53 alterations, and 67% had biallelic TP53 alterations.

Survival follow-up is ongoing, and several patients remain alive and under follow-up, providing the opportunity for further maturation of the dataset over time.

“These results further support the potential of bexmarilimab in frontline TP53 wild-type and mutated HR-MDS patients, where significant unmet medical need remains,” said Dr. Petri Bono, Chief Medical Officer of Faron Pharmaceuticals. “The data provide additional support as we continue preparations for BEXERA, our planned randomized study evaluating bexmarilimab in combination with azacitidine in frontline HR-MDS patients. We look forward to presenting the detailed full BEXMAB dataset at an upcoming scientific meeting later this year.”

For more information, please contact:

IR Partners, Finland
(Media)

Kare Laukkanen
+358 50 553 9535 / +44 7 469 766 223
kare.laukkanen@irpartners.fi
FINN Partners, US
(Media) 
Alyssa Paldo 		 +1 847 791-8085 
alyssa.paldo@finnpartners.com
Cairn Financial Advisers LLP
(Nominated Adviser and Broker)
Sandy Jamieson, Jo Turner		 +44 (0) 207 213 0880
Sisu Partners Oy
(Certified Adviser on Nasdaq First North)
Juha Karttunen
Jukka Järvelä		 +358 (0)40 555 4727
+358 (0)50 553 8990

About bexmarilimab

Bexmarilimab is Faron’s wholly owned, investigational immunotherapy designed to overcome resistance to existing treatments and optimize clinical outcomes, by targeting myeloid cell function and igniting the immune system. Bexmarilimab binds to Clever-1, an immunosuppressive receptor found on macrophages leading to tumor growth and metastases (i.e. helps cancer evade the immune system). By targeting the Clever-1 receptor on macrophages, bexmarilimab alters the tumor microenvironment, reprogramming macrophages from an immunosuppressive (M2) state to an immunostimulatory (M1) one, upregulating interferon production and priming the immune system to attack tumors and sensitizing cancer cells to standard of care.

About Faron Pharmaceuticals Ltd.

Faron (AIM: FARN, First North: FARON) is a global, clinical-stage biopharmaceutical company, focused on tackling cancers via novel immunotherapies. Its mission is to bring the promise of immunotherapy to a broader population by uncovering novel ways to control and harness the power of the immune system. The Company’s lead asset is bexmarilimab, a novel anti-Clever-1 humanized antibody, with the potential to remove immunosuppression of cancers through reprogramming myeloid cell function. Bexmarilimab is being investigated in Phase 1/2 clinical trials as a potential therapy for patients with hematological cancers in combination with other standard treatments. Further information is available at www.faron.com.

Forward-Looking Statements

Certain statements in this announcement are, or may be deemed to be, forward-looking statements. Forward looking statements are identified by their use of terms and phrases such as ”believe”, ”could”, “should”, “expect”, “hope”, “seek”, ”envisage”, ”estimate”, ”intend”, ”may”, ”plan”, ”potentially”, ”will” or the negative of those, variations or comparable expressions, including references to assumptions. These forward-looking statements are not based on historical facts but rather on the Directors’ current expectations and assumptions regarding the Company’s future growth, results of operations, performance, future capital and other expenditures (including the amount, nature and sources of funding thereof), competitive advantages, business prospects and opportunities. Such forward-looking statements reflect the Directors’ current beliefs and assumptions and are based on information currently available to the Directors.

A number of factors could cause actual results to differ materially from the results and expectations discussed in the forward-looking statements, many of which are beyond the control of the Company. In addition, other factors which could cause actual results to differ materially include the ability of the Company to successfully license its programs within the anticipated timeframe or at all, risks associated with vulnerability to general economic and business conditions, competition, environmental and other regulatory changes, actions by governmental authorities, the availability of capital markets or other sources of funding, reliance on key personnel, uninsured and underinsured losses and other factors. Although any forward-looking statements contained in this announcement are based upon what the Directors believe to be reasonable assumptions, the Company cannot assure investors that actual results will be consistent with such forward-looking statements. Accordingly, readers are cautioned not to place undue reliance on forward-looking statements.

FARON PHARMACEUTICALS LTD: HOLDING(S) IN COMPANY

Faron Pharmaceuticals Ltd | Company announcement | July 24, 2026 at 09:00:00 EEST

TR-1: Standard form for notification of major holdings

NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer in Microsoft Word format if possible) i
1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached ii: Faron Pharmaceuticals OY
1b. Please indicate if the issuer is a non-UK issuer (please mark with an “X” if appropriate)
Non-UK issuer X
2. Reason for the notification (please mark the appropriate box or boxes with an “X”)
An acquisition or disposal of voting rights X
An acquisition or disposal of financial instruments
An event changing the breakdown of voting rights
Other (please specify) iii:
3. Details of person subject to the notification obligation iv
Name Heights Capital Management, Inc.
City and country of registered office (if applicable) San Francisco, California
4. Full name of shareholder(s) (if different from 3.) v
Name CVI Investments, Inc.
City and country of registered office (if applicable) Cayman Islands
5. Date on which the threshold was crossed or reached vi: 22/07/2026
6. Date on which issuer notified (DD/MM/YYYY): 23/07/2026
7. Total positions of person(s) subject to the notification obligation
% of voting rights attached to shares (total of 8. A) % of voting rights through financial instruments
(total of 8.B 1 + 8.B 2)		 Total of both in % (8.A + 8.B) Total number of voting rights held in issuer (8.A + 8.B) vii
Resulting situation on the date on which threshold was crossed or reached 7.99% 12.53% 20.52% 46,774,836
Position of previous notification (if
applicable)		 8.88% 12.53% 21.41%
8. Notified details of the resulting situation on the date on which the threshold was crossed or reached viii
A: Voting rights attached to shares
Class/type of
shares
ISIN code (if possible)		 Number of voting rights ix % of voting rights
Direct
(DTR5.1)		 Indirect
(DTR5.2.1)		 Direct
(DTR5.1)		 Indirect
(DTR5.2.1)
18,214,836 28,560,000 7.99% 12.53%
SUBTOTAL 8. A 46,774,836 20.52%
B 1: Financial Instruments according to DTR5.3.1R (1) (a)
Type of financial instrument Expiration
date x		 Exercise/
Conversion Period xi		 Number of voting rights that may be acquired if the instrument is
exercised/converted.		 % of voting rights
Convertible Bond 08/02/2027 Anytime until maturity 11,760,000 5.16%
Convertible Bond 12/02/2028 Anytime until maturity 16,800,000 7.37%
SUBTOTAL 8. B 1 28,560,000 12.53%
B 2: Financial Instruments with similar economic effect according to DTR5.3.1R (1) (b)
Type of financial instrument Expiration
date x		 Exercise/
Conversion Period xi		 Physical or cash
Settlement xii		 Number of voting rights % of voting rights
SUBTOTAL 8.B.2
9. Information in relation to the person subject to the notification obligation (please mark the
applicable box with an “X”)
Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer xiii
Full chain of controlled undertakings through which the voting rights and/or the
financial instruments are effectively held starting with the ultimate controlling natural person or legal entity (please add additional rows as necessary) xiv
Name xv % of voting rights if it equals or is higher than the notifiable threshold % of voting rights through financial instruments if it equals or is higher than the notifiable threshold Total of both if it equals or is higher than the notifiable threshold
Heights Capital Management, Inc. 7.99% 12.53% 20.52%
CVI Investments, Inc. 7.99% 12.53% 20.52%
10. In case of proxy voting, please identify:
Name of the proxy holder
The number and % of voting rights held
The date until which the voting rights will be held
11. Additional information xvi
None
Place of completion London, United Kingdom
Date of completion 23.07.2026

Faron Pharmaceuticals Ltd: Grant of Options

Faron Pharmaceuticals Ltd | Company announcement | July 01, 2026 at 13:00:00 EEST

TURKU, FINLAND – Faron Pharmaceuticals Ltd. (AIM: FARN, First North: FARON), a clinical-stage biopharmaceutical company focused on tackling cancers via novel immunotherapies, today announces that the Company’s board has confirmed the grant of a total of 2,173,000 options over ordinary shares in the Company (“Options”) under the Company’s Share Option Plan 2026.

The Options have been allocated under the Share Option Plan 2026 and are exercisable after 1 June 2029, vesting 100%. The exercise price for Options allocated under the Share Option Plan is € 0.50 per share based on the resolution of the Annual General Meeting on 4 May 2026 and € 0.53 for the recipients of options who are US nationals. The terms of the Share Option Plan 2026 are available on the Company’s website.

The granted 2,173,000 Options entitle the option holders to subscribe for a total of 2,173,000 new ordinary shares in the Company, if exercised in full, and represent 0.95 % of the fully diluted ordinary share capital of the Company on the grant date.

Included in the number of Options granted are the following Options which were issued to directors and other persons discharging managerial responsibilities (“PDMRs”):

Director Options granted
Colin Bond 60,000
Christine Roth 60,000
George Golumbeski 60,000
Juho Jalkanen 220,000
Marie-Louise Fjällskog 60,000
Tuomo Pätsi 200,000
Total directors 660,000
Other PDMR
Maija Hollmén 38,000
Vesa Karvonen 120,000
Jurriaan Dekkers 170,000
Petri Bono 170,000
Ralph Hughes 120,000
Kaisa Kyttä 100,000
Joab Wiliamson 100,000
Total other PDMRs 818,000
Total Company personnel 695,000

For more information, please contact:

IR Partners, Finland
(Media)
Kare Laukkanen		 +358 50 553 9535 / +44 7 469 766 223
kare.laukkanen@irpartners.fi
FINN Partners, US
(Media) 
Alyssa Paldo 		 +1 847 791-8085 
alyssa.paldo@finnpartners.com
Cairn Financial Advisers LLP
(Nominated Adviser and Broker)
Sandy Jamieson, Jo Turner		 +44 (0) 207 213 0880
Sisu Partners Oy
(Certified Adviser on Nasdaq First North)
Juha Karttunen
Jukka Järvelä		 +358 (0)40 555 4727
+358 (0)50 553 8990

About BEXMAB

The BEXMAB study is an open-label Phase I/II clinical trial investigating bexmarilimab in combination with standard of care (SoC) in the aggressive hematological malignancies of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). The primary objective is to determine the safety and tolerability of bexmarilimab in combination with SoC (azacitidine) treatment. Directly targeting Clever-1 could limit the replication capacity of cancer cells, increase antigen presentation, ignite an immune response, and allow current treatments to be more effective. Clever-1 is highly expressed in both AML and MDS and associated with therapy resistance, limited T cell activation and poor outcomes.

About Bexmarilimab

Bexmarilimab is Faron’s wholly owned, investigational immunotherapy designed to overcome resistance to existing treatments and optimize clinical outcomes, by targeting myeloid cell function and igniting the immune system. Bexmarilimab binds to Clever-1, an immunosuppressive receptor found on macrophages leading to tumor growth and metastases (i.e. helps cancer evade the immune system). By targeting the Clever-1 receptor on macrophages, bexmarilimab alters the tumor microenvironment, reprogramming macrophages from an immunosuppressive (M2) state to an immunostimulatory (M1) one, upregulating interferon production and priming the immune system to attack tumors and sensitizing cancer cells to standard of care.

About Faron Pharmaceuticals Ltd.

Faron (AIM: FARN, First North: FARON) is a global, clinical-stage biopharmaceutical company, focused on tackling cancers via novel immunotherapies. Its mission is to bring the promise of immunotherapy to a broader population by uncovering novel ways to control and harness the power of the immune system. The Company’s lead asset is bexmarilimab, a novel anti-Clever-1 humanized antibody, with the potential to remove immunosuppression of cancers through reprogramming myeloid cell function. Bexmarilimab is being investigated in Phase I/II clinical trials as a potential therapy for patients with hematological cancers in combination with other standard treatments. Further information is available at www.faron.com.

Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014
1 Details of the person discharging managerial responsibilities/person closely associated
a. Name a. Colin Bond
b. Christine Roth
c. George Golumbeski
d. Juho Jalkanen
e. Marie-Louise Fjällskog
f. Tuomo Pätsi
g. Maija Hollmén
h. Vesa Karvonen
i. Jurriaan Dekkers
j. Petri Bono
k. Ralph Hughes
l. Kaisa Kyttä
m. Joab Williamson
2 Reason for notification  
 
 
a. Position/Status Person discharging managerial responsibilities/person closely associated
b. Initial notification/
Amendment		 Initial notification
3 Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a. Name Faron Pharmaceuticals Oy
b. LEI 7437009H31TO1DC0EB42
4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a. Description of the financial instrument, type of instrument

Identification Code

 Options over new ordinary shares

ISIN: FI4000153309
b. Nature of the transaction Grant of options made under the Faron Share Option Plan 2026. The exercise price for Options allocated under the Share Option Plan is € 0.50 per share and € 0.53 for the recipients of options who are US nationals.
c. Price(s) and volume(s)
Price(s) Volume(s)
a. € 0.50
b. € 0.53
c. € 0.53
d. € 0.50
e. € 0.53
f. € 0.50
g. € 0.50
h. € 0.50
i. € 0.50
j. € 0.50
k. € 0.50
l. € 0.50
m. € 0.50		 60,000
60,000
60,000
300,000
60,000
200,000
38,000
120,000
170,000
170,000
120,000
100,000
100,000
 
 
d. Aggregated information
 
– Aggregated Volume
 
– Price		  
 
Nil
 
 
e. Date of the transaction
f. Place of the transaction Turku
 

FARON PHARMACEUTICALS LTD: HOLDING(S) IN COMPANY

Faron Pharmaceuticals Ltd | Company announcement | June 22, 2026 at 16:00:00 EEST

Standard form for notification of major holdings

NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FIN-FSA)
1. Identity of the issuer:
FARON PHARMACEUTICALS OY
2. Reason for the notification (please tick the appropriate box or boxes):

☐ An acquisition or disposal of shares or voting rights
☒ An acquisition or disposal of financial instruments
☐ An event changing the breakdown of shares or voting rights
☐ Other (please specify): Click here to enter text.
3. Details of person subject to the notification obligation:
Name:
Bank of America Corporation		 City and country of residence:
Wilmington, DE, United States of America
4. Full name of shareholder(s) (if different from 3.):
–
5. Date on which the threshold was crossed or reached:
17.6.2026
6. Total positions of person(s) subject to the notification obligation:
% of shares and voting rights
(total of 7.A)		 % of shares and voting rights through financial instruments
(total of 7.B)		 Total of both in % (7.A + 7.B) Total number of shares and voting rights of issuer
Resulting situation on the date on which threshold was crossed or reached 0.17 8.73 8.90 227,881,315
Position of previous notification (if applicable) 0.12 9.99 10.11
7. Notified details of the resulting situation on the date on which the threshold was crossed or reached:
A: Shares and voting rights
Class/type of
shares
ISIN code (if possible)		 Number of shares and voting rights % of shares and voting rights
Direct
(SMA 9:5)		 Indirect
(SMA 9:6 and 9:7)		 Direct
(SMA 9:5)		 Indirect
(SMA 9:6 and 9:7)
FI4000153309 0 377,478 0 0.17
– – – – –
– – – – –
SUBTOTAL A 377,478 0.17
B: Financial Instruments according to SMA 9:6a
Type of financial instrument Expiration
date		 Exercise/
Conversion Period		 Physical or cash settlement Number of shares and voting rights % of shares and voting rights
Rights of Use n/a n/a n/a 19,584,472 8.59
swaps 15/10/2027 n/a Cash 314,746 0.14
– – – – – –
SUBTOTAL B 19,899,218 8.73

8. Information in relation to the person subject to the notification obligation (please tick the applicable box):

☐ Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer.

☒ Full chain of controlled undertakings through which the voting rights and/or the
financial instruments are effectively held starting with the ultimate controlling natural person or legal entity:
Name % of shares and voting rights % of shares and voting rights through financial instruments Total of both
Bank of America Corporation
NB Holdings Corporation
BofAML Jersey Holdings Limited
BofAML EMEA Holdings 2 Limited
ML UK Capital Holdings Limited
Merrill Lynch International
Bank of America Corporation
NB Holdings Corporation
BAC North America Holding Company
Bank of America, National Association
Bank of America Corporation
NB Holding Corporation
Bofa Securities, Inc 8.59% 8.59%
9. In case of proxy voting: [name of the proxy holder] will cease to hold [% and number] voting rights as of Click here to enter a date.
10. Additional information:
–

Done at London, United Kingdom on 18.6.2026.

FARON PHARMACEUTICALS LTD: HOLDING(S) IN COMPANY

Faron Pharmaceuticals Ltd | Company announcement | June 17, 2026 at 16:30:00 EEST

TR-1: Standard form for notification of major holdings

NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) i
1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached ii: Faron Pharmaceuticals Ltd
1b. Please indicate if the issuer is a non-UK issuer (please mark with an “X” if appropriate)
Non-UK issuer x
2. Reason for the notification (please mark the appropriate box or boxes with an “X”)
An acquisition or disposal of voting rights x
An acquisition or disposal of financial instruments
An event changing the breakdown of voting rights x
Other (please specify) iii:
3. Details of person subject to the notification obligation iv
Name Timo Syrjälä
City and country of registered office (if applicable) Monaco
4. Full name of shareholder(s) (if different from 3.) v
Name Acme Investments SPF Sarl
City and country of registered office (if applicable) Luxembourg
5. Date on which the threshold was crossed or reached vi: 11.6.2026
6. Date on which issuer notified (DD/MM/YYYY): 16.6.2026
7. Total positions of person(s) subject to the notification obligation
% of voting rights attached to shares (total of 8. A) % of voting rights through financial instruments
(total of 8.B 1 + 8.B 2)		 Total of both in % (8.A + 8.B) Total number of voting rights held in issuer (8.A + 8.B) vii
Resulting situation on the date on which threshold was crossed or reached 6.46% 14.712.470
Position of previous notification (if
applicable)		 7.77% 15.509.443
8. Notified details of the resulting situation on the date on which the threshold was crossed or reached viii
A: Voting rights attached to shares
Class/type of
shares
ISIN code (if possible)		 Number of voting rights ix % of voting rights
Direct
(DTR5.1)		 Indirect
(DTR5.2.1)		 Direct
(DTR5.1)		 Indirect
(DTR5.2.1)
FI4000153309 5.544.672 9.167.798 2.43% 4.02%
SUBTOTAL 8. A 14.712.470

6.46%
B 1: Financial Instruments according to DTR5.3.1R (1) (a)
Type of financial instrument Expiration
date x		 Exercise/
Conversion Period xi		 Number of voting rights that may be acquired if the instrument is
exercised/converted.		 % of voting rights
SUBTOTAL 8. B 1
B 2: Financial Instruments with similar economic effect according to DTR5.3.1R (1) (b)
Type of financial instrument Expiration
date x		 Exercise/
Conversion Period xi		 Physical or cash
Settlement xii		 Number of voting rights % of voting rights
SUBTOTAL 8.B.2
9. Information in relation to the person subject to the notification obligation (please mark the
applicable box with an “X”)
Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer xiii
Full chain of controlled undertakings through which the voting rights and/or the
financial instruments are effectively held starting with the ultimate controlling natural person or legal entity (please add additional rows as necessary) xiv		 X
Name xv % of voting rights if it equals or is higher than the notifiable threshold % of voting rights through financial instruments if it equals or is higher than the notifiable threshold Total of both if it equals or is higher than the notifiable threshold
Timo Syrjälä (Direct) 2.43% 2.43%
Acme Investments SPF Sarl (Indirect) 4.02% 4.02%
10. In case of proxy voting, please identify:
Name of the proxy holder
The number and % of voting rights held
The date until which the voting rights will be held
11. Additional information Faron has changed 11.6.2026 the way the flagging responsibility is defined by calculating also shares registered and issued to Faron and still owned by company itself. However, shares owned by Faron itself cannot be calculated as capable to vote in shareholders meetings. New total number of Faron shares registered 227.881.315.
Place of completion Monaco
Date of completion 16.6.2026

FARON PHARMACEUTICALS LTD: HOLDING(S) IN COMPANY

Faron Pharmaceuticals Ltd | Company announcement | June 17, 2026 at 09:00:00 EEST

Standard form for notification of major holdings

NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FIN-FSA)
1. Identity of the issuer:
FARON PHARMACEUTICALS OY
2. Reason for the notification (please tick the appropriate box or boxes):

☐ An acquisition or disposal of shares or voting rights
☒ An acquisition or disposal of financial instruments
☐ An event changing the breakdown of shares or voting rights
☐ Other (please specify): Click here to enter text.
3. Details of person subject to the notification obligation:
Name:
Bank of America Corporation		 City and country of residence:
Wilmington, DE, United States of America
4. Full name of shareholder(s) (if different from 3.):
–
5. Date on which the threshold was crossed or reached:
12.6.2026
6. Total positions of person(s) subject to the notification obligation:
% of shares and voting rights
(total of 7.A)		 % of shares and voting rights through financial instruments
(total of 7.B)		 Total of both in % (7.A + 7.B) Total number of shares and voting rights of issuer
Resulting situation on the date on which threshold was crossed or reached 0.12 9.99 10.11 206,411,888
Position of previous notification (if applicable) 0.13 10.07 10.20
7. Notified details of the resulting situation on the date on which the threshold was crossed or reached:
A: Shares and voting rights
Class/type of
shares
ISIN code (if possible)		 Number of shares and voting rights % of shares and voting rights
Direct
(SMA 9:5)		 Indirect
(SMA 9:6 and 9:7)		 Direct
(SMA 9:5)		 Indirect
(SMA 9:6 and 9:7)
FI4000153309 0 246,335 0 0.12
– – – – –
– – – – –
SUBTOTAL A 246,335 0.12
B: Financial Instruments according to SMA 9:6a
Type of financial instrument Expiration
date		 Exercise/
Conversion Period		 Physical or cash settlement Number of shares and voting rights % of shares and voting rights
Rights of Use n/a n/a n/a 20,374,993 9.87
Swaps 15/10/2027 n/a Cash 245,294 0.12
– – – – – –
SUBTOTAL B 20,620,287 9.99

8. Information in relation to the person subject to the notification obligation (please tick the applicable box):

☐ Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer.

☒ Full chain of controlled undertakings through which the voting rights and/or the
financial instruments are effectively held starting with the ultimate controlling natural person or legal entity:
Name % of shares and voting rights % of shares and voting rights through financial instruments Total of both
– – – –
– – – –
– – – –

–

 – – –
– – – –
9. In case of proxy voting: [name of the proxy holder] will cease to hold [% and number] voting rights as of Click here to enter a date.
10. Additional information:

Done at London, United Kingdom on 15.6.2026.
Back to top